Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Two-part, Phase I/II, Randomized, Single-blind Study to Evaluate the Efficacy and Safety of UMC119-06-05 in Older Adults With Pre-frailty & Frailty

Authors not listed

Meribank Biotech Co., Ltd. · 2024

Stem-cell exhaustion Stem-cell therapy Human Randomized controlled trial

Abstract

This Phase I/II study is designed to evaluate the efficacy and safety of UMC119-06-05, an allogeneic umbilical cord mesenchymal stem cells, in older adults with frailty syndrome. This study will also seek to determine the long-term safety and clinical outcomes of UMC119-06-05 in subjects with frailty syndrome, which will provide information for subsequent clinical trials with UMC119-06-05.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-23 MST

Cite this

APA

Anonymous. (2024). A Two-part, Phase I/II, Randomized, Single-blind Study to Evaluate the Efficacy and Safety of UMC119-06-05 in Older Adults With Pre-frailty & Frailty. <em>Meribank Biotech Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT06501066

Vancouver

Anonymous. A Two-part, Phase I/II, Randomized, Single-blind Study to Evaluate the Efficacy and Safety of UMC119-06-05 in Older Adults With Pre-frailty & Frailty. Meribank Biotech Co., Ltd.. 2024.

BibTeX

@misc{anon2024ATwopa, title = {A Two-part, Phase I/II, Randomized, Single-blind Study to Evaluate the Efficacy and Safety of UMC119-06-05 in Older Adults With Pre-frailty & Frailty}, author = {Anonymous}, journal = {Meribank Biotech Co., Ltd.}, year = {2024}, }